Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
BMY > SEC Filings for BMY > Form 8-K on 9-Jun-2014All Recent SEC Filings

Show all filings for BRISTOL MYERS SQUIBB CO



Change in Directors or Principal Officers, Financial Statements and Exhib

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) (d) On June 5, 2014, the Board of Directors of Bristol-Myers Squibb Company (the "Company") appointed Giovanni Caforio, M.D., to serve as the Company's Chief Operating Officer and elected Dr. Caforio as a member of the Board of Directors. The size of the Board of Directors was increased to twelve in connection with Dr. Caforio's election.

Dr. Caforio is 49 years old and has worked for the Company since 2000 in roles of increasing seniority. He served as the Company's Executive Vice President and Chief Commercial Officer from November 2013 through June 2014. Prior to that role, he served as President, U.S. In 2011, Dr. Caforio served as Senior Vice President, Oncology and Immunoscience, Global Commercialization. From 2009 through 2010, he served as Senior Vice President, Oncology, Global Commercialization, and from 2007 through 2009 he served as Senior Vice President, U.S. Oncology.

Due to his employment with the Company, the Board of Directors has determined that Dr. Caforio is not independent under the New York Stock Exchange Listing Standards or the independence standards adopted by the Board of Directors. Dr. Caforio will stand for election by the Company's stockholders at the Annual Meeting of Stockholders in May 2015.

Dr. Caforio was not selected as a director pursuant to any arrangement or understanding between him and any other person. There are no related party transactions between the Company and Dr. Caforio.

Dr. Caforio will receive compensation for his service as Chief Operating Officer in accordance with the Company's standard executive compensation program. Dr. Caforio will not be compensated for his service as a director of the Company.

A copy of the press release announcing Dr. Caforio's election is attached to this report as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release dated June 9, 2014.

  Add BMY to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for BMY - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.